FDA grants orphan drug status to Madison company’s drug treatment

Noted: The drug Co-D is developing, called Triolimus, was developed by professor Glen Kwon at the University of Wisconsin-Madison. It contains three proven anti-cancer agents in a nontoxic, nanoparticle carrier, the company said. Patients with the blood vessel cancer, called angiosarcoma, have an average survival rate of less than a year.